Document is current
Any future updates will be listed below
-
Authors
Toor, Kabirraaj
Middleton, Mark R.
Chan, Keith
Amadi, Adenike
Moshyk, Andriy
Kotapati, Srividya
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb Company (Not applicable)
- License Information
-
More Information
Article History
Received: 2 July 2020
Accepted: 16 October 2020
First Online: 5 January 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: KT and KC are employees of Precision HEOR, which received funding from Bristol Myers Squibb for the current work. MRM has served as an advisor to Amgen, Array Biopharma, BiolineRx, Bristol Myers Squibb, GlaxoSmithKline, Immunocore, Kineta, Novartis, Rigontec, Roche, and Silicon Therapeutics; has received institutional research support from Array Biopharma, AstraZeneca, BiolineRx, Bristol Myers Squibb, Eisai, GlaxoSmithKline, Immunocore, Merck, Merck Sharp & Dohme, Millenium, Novartis, Pfizer, Regeneron, Replimune, Rigontec, and Roche; has received travel support from Immunocore, Merck, Merck Sharp & Dohme, and Replimune; and is a member of an independent data safety monitoring committee for Eisai and Merck/Merck Sharp & Dohme. AA and AM are employees of and stockholders in Bristol Myers Squibb. SK is an employee of Bristol Myers Squibb.
